Welcome to our dedicated page for IGC Pharma SEC filings (Ticker: IGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IGC Pharma, Inc. filings document a clinical-stage biotechnology issuer with common stock listed on NYSE American under the symbol IGC. The company's regulatory disclosures cover material-event reports, operating and financial results, clinical and regulatory updates tied to Alzheimer's disease programs, and capital-structure matters including promissory note financing and authorized share changes.
Form 8-K disclosures also record amendments to governing documents, the fiscal year-end change to December 31, shareholder voting results, board election and auditor ratification matters, and equity incentive share approvals. These filings frame the company's governance, financing arrangements, reporting calendar and development-stage disclosure profile.
IGC Pharma, Inc. reported a charter amendment that significantly expands its capacity to issue common shares. Effective December 12, 2025, the company increased its authorized common stock from 150,000,000 to 600,000,000 shares, following approval by stockholders at the Annual Stockholders Meeting held on October 10, 2025. Total authorized shares of all classes rose from 150,000,000 to 601,000,000, including 1,000,000 shares of preferred stock that were unchanged.
The aggregate par value of all par value shares increased from $15,100.00 to $60,100.00, reflecting the larger number of authorized shares. The amendment was filed with and accepted by the Maryland State Department of Assessments and Taxation, and a copy of the Articles of Amendment is included as an exhibit to this report.
IGC Pharma, Inc. has filed an amended resale registration statement covering up to 978,235 shares of common stock, including 390,000 shares issuable upon exercise of stock options, for sale by existing security holders. The company itself is not selling any shares in this transaction and will not receive proceeds from these sales, though it will cover registration-related expenses.
The registered shares include 588,235 shares issued under a 2024 share purchase agreement with Moran Global Strategies, Inc. for $200,000 at $0.34 per share, and options granted to advisors for 390,000 shares at exercise prices around the current trading range. IGC Pharma is a clinical-stage company focused on using AI to develop treatments for Alzheimer’s disease, with lead candidate IGC-AD1 in a Phase 2 trial for agitation in Alzheimer’s dementia. The company notes that investing in its securities involves a high degree of risk and directs readers to detailed risk factors.
IGC Pharma, Inc. has filed a resale registration covering up to 978,235 shares of common stock, consisting of 588,235 outstanding shares and 390,000 shares issuable upon exercise of stock options. All shares may be sold from time to time by the selling stockholders, and the company will not sell shares or receive any proceeds from these resales. IGC will bear the registration expenses, while selling holders will bear their own selling costs.
The registered shares stem from equity issued or option grants under agreements with Moran Global Strategies, The Gutman Group, and advisor Professor Pablo Arbelaez. IGC’s common stock trades on the NYSE American under the symbol IGC, and the closing price on November 13, 2025 was $0.36 per share. IGC is a clinical-stage pharmaceutical company focused on AI-enabled therapies for Alzheimer’s disease, with lead candidate IGC-AD1 in a Phase 2 trial for agitation in Alzheimer’s patients. The prospectus emphasizes that investing in these securities involves a high degree of risk.
IGC Pharma filed its quarterly report for the period ended September 30, 2025. The company reported revenue of $191 thousand for the quarter and a net loss of $1.821 million. R&D expenses rose to $1.588 million as the Phase 2 trial of IGC‑AD1 advanced past the 50% enrollment mark.
Other income was $1.078 million, reflecting a gain from the sale of assets at the Vancouver, Washington facility. The transaction delivered approximately $2.7 million in consideration versus about $1.5 million of carrying value, and included preferential supply rights and a contingent 10% interest on a potential future sale by the buyer.
Cash and cash equivalents were $1.105 million at September 30, 2025, with working capital of $490 thousand. The company amended and extended its $12 million credit facility, reducing the annual facility fee and setting interest at the certificate of deposit rate plus a 1.2% margin. For the six months, revenue was $519 thousand and net cash used in operations was $3.497 million. Common shares outstanding were 91,959,112 as of September 30, 2025.
IGC Pharma completed the previously announced sale of certain equipment, inventory, and operating assets from its Holi Hemp LLC Vancouver, Washington facility. The transactions under the Sale of Assets and Manufacturing Agreement with Wellness Essentials Northwest LLC were consummated on November 13, 2025 for a fair value of approximately $2.7 million, following satisfaction of closing conditions.
The company filed unaudited pro forma condensed consolidated financial statements reflecting this disposition, including a balance sheet as of June 30, 2025 and a statement of operations for the three months ended June 30, 2025. The agreement is available as an exhibit, providing detailed terms of the asset sale and manufacturing arrangements.
IGC Pharma (IGC) reported a director’s stock option grant on a Form 4. The filing shows 750,000 options with a $0.35 exercise price tied to a transaction dated 10/17/2025. According to the footnote, the options vest equally over three years starting March 31, 2026, and expire on March 31, 2038. Following the grant, 750,000 derivative securities were beneficially owned, held directly.
IGC Pharma (IGC) reported an insider equity award. A director received 500,000 stock options on 10/17/2025 with an exercise price of $0.35 per share, according to a Form 4. The award reflects equity-based compensation and was recorded as directly owned derivative securities.
The options vest equally over three years starting on March 31, 2026, and carry an expiration date of March 31, 2038. Form 4s disclose changes in insiders’ beneficial ownership; option grants like this typically do not involve immediate cash transactions and do not represent an open-market purchase or sale.
IGC Pharma (IGC) reported an insider equity award. A director was granted 500,000 stock options at an exercise price of $0.35 per share on 10/17/2025.
The options vest equally over three years starting on March 31, 2026 and expire on March 31, 2038. The filing lists the holdings as direct ownership. This reflects routine equity-based compensation and does not involve an immediate cash transaction.
IGC Pharma (IGC) filed a Form 4 reporting insider equity activity on 10/17/2025. The reporting person, a Director and PFO, made a gift of 50,000 shares of common stock. Following the transaction, beneficial ownership of common shares was 1,134,252 (direct).
The filing also reports two option grants at an exercise price of $0.35: 1,000,000 options vesting equally over three years starting March 31, 2026 (expiration 03/31/2038), and 500,000 options that vest upon achievement of Board-set milestones (expiration 03/31/2036). These awards reflect equity compensation and do not involve cash transactions at grant.